Aptevo Therapeutics Inc., a clinical-stage biotechnology company, is working on developing immunotherapeutic candidates in the United States for various types of cancer. Its lead clinical candidate, APVO436, is a bispecific T-cell engaging antibody candidate, which is in Phase 1b clinical trials for acute myelogenous leukemia and myelodysplastic syndrome. The company has some preclinical candidates in the pipeline, such as ALG.APV-527, an investigational bispecific ADAPTIR candidate, which targets 4-1BB (CD137) and 5T4, a tumor antigen expressed in different types of cancers. Additionally, the company has developed APVO603, a dual agonist bispecific antibody that targets 4-1BB and OX40. The company is also working on APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology, which enhances the biodistribution of drugs to PSMA-positive tumors for the treatment of prostate cancer. Aptevo Therapeutics Inc. has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. The company, headquartered in Seattle, Washington, was incorporated in 2016.
Aptevo Therapeutics Inc.'s ticker is APVO
The company's shares trade on the NASDAQ stock exchange
They are based in Seattle, Washington
There are 51-200 employees working at Aptevo Therapeutics Inc.
It is https://aptevotherapeutics.com/
Aptevo Therapeutics Inc. is in the Healthcare sector
Aptevo Therapeutics Inc. is in the Biotechnology industry
The following five companies are Aptevo Therapeutics Inc.'s industry peers: